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ABSTRACT
Objectives: In our study, the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography 
(F-18 FDG PET/CT) in determining lymph node metastasis of endometrial cancer was evaluated. 
Material and methods: The present retrospectively registered study included 80 patients with endometrial cancer who 
underwent PET/CT in preoperative period. The patients underwent total hysterectomy with bilateral salpingo-oophorectomy 
and lymph node dissection. Lymph node status was evaluated in histopathologic examination and PET/CT imaging and, 
the results were compared.
Results: There were 80 patients (mean age 62 years) in the present study. Lymph node metastasis was detected in five pa-
tients, whereas 75 patients had no lymph node metastasis. A total of 1,471 lymph nodes were examined histopathologically, 
revealing benign findings in 1,433 (pelvic = 1018, paraaortic = 415) and malignant findings in 38 (pelvic = 28, paraaortic = 10) 
lymph nodes. The accuracy, sensitivity and specificity of PET/CT in determining lymph node metastasis was 95%, 80% and 
96% in patient-based evaluation, and 97.4%, 78.9% and 98.6% in lymph node-based evaluation, respectively. The detec-
tion sensitivity of PET/CT was 0%, 81.4% and 100% in metastatic lymph nodes with a short diameter of ≤ 4 mm, 5–9 mm  
and ≥ 10 mm, respectively. PET/CT could detect 73.3% of metastatic lymph nodes that had < 10 mm short diameter.
Conclusions: PET/CT is useful method in detecting lymph node metastasis especially that are disregarded by CT or MR in 
endometrial cancer. Although PET/CT doesn’t fully replace the surgical staging, its utilization in preoperative period may 
guide surgical procedure.
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INTRODUCTION
The most common gynecological neoplasm in industri-
alized countries is endometrial cancer [1]. The International 
Federation of Gynecology and Obstetrics (FIGO) recom-
mends total hysterectomy with bilateral salpingo-oophorec-
tomy and lymph node dissection for surgical staging of en-
dometrial cancer [2, 3]. Prognosis in such patients is affected 
by numerous factors, such as tumor histology, grade, lymph 
node metastasis, depth of myometrial invasion, cervical 
invasion, lymphovascular invasion and patient’s age [4, 5]. 
Pelvic lymph nodes are a common site of involvement in 
endometrial cancer, and patients with lymph node metas-
tasis have considerably lower survival than patients without 
nodal metastasis [6, 7]. Randomized studies suggest that 
a routine systematic pelvic lymphadenectomy may con-
tribute to surgical staging without any effect on survival 
in early-stage endometrial cancer [8, 9]. In this regard, the 
major role of lymphadenectomy is to decide on adjuvant 
therapy by contributing to the staging and the prediction of 
prognosis in endometrial cancer [10]. Lymph node dissec-
tion may cause significant morbidity, and metastasis may 
not be found in patients undergoing dissection [10]. Thus, 
the accurate prediction of lymph node status in preoperative 
period is important if futile lymph node dissection is to be 
avoided [11]. Magnetic resonance (MR) and computed to-
mography (CT) may fail to determine lymph node metastasis 
accurately [12, 13]. Fluorine-18 fluorodeoxyglucose positron 
emission tomography/computed tomography (F-18 FDG 
PET/CT) is a commonly used method for the diagnosis and 
staging of numerous malignancies, and in evaluating re-
sponse to therapy, providing both functional and anatomi-
cal information. It is suggested that functional changes that 
are detectable on a PET/CT precede morphological changes 
that can be detected using conventional CT and MR [14]. 
566
Ginekologia Polska 2019, vol. 90, no. 10
www. journals.viamedica.pl/ginekologia_polska
Objectıves
The authors of the present study assess the role of 
F-18 FDG PET/CT in determining lymph node metastasis 
of endometrial cancer.
 MATERIAL AND METHODS
Patients
This retrospective study included 80 patients with a his-
topathological diagnosis of endometrial cancer who un-
derwent preoperative F-18 FDG PET/CT in our department 
between February 2010 and March 2014. 
Surgery
All patients underwent total hysterectomy with bilateral 
salpingo-oophorectomy and pelvic lymphadenectomy (ex-
ternal iliac, superficial and deep common iliac lymph nodes). 
There were positive lymph nodes in the pelvic and/or par-
aaortic areas on PET/CT scans in 7 patients. Furthermore, 
there were 43 patients with suspected for paraaortic lymph 
node metastasis during surgery. Therefore, these fifty pa-
tients underwent an additional paraaortic lymphadenecto-
mies (precaval and paracaval, superficial and deep interaor-
tocaval and paraaortic lymph nodes up to the renal vessels). 
All lymph nodes were evaluated by intraoperative inspec-
tion and palpation. Palpable, enlarged or fixed lymph nodes 
were regarded suspicious for malignancy. Furthermore, 
frozen section of uterine resection was evaluated in terms of 
tumor size, grade, histology and myometrial and cervical in-
vasion status. Patients with myometrial invasion < 50% and 
without cervical invasion endometrioid cancer (grade 1 or 
tumor diameter < 2 cm grade 2) were considered to be at low 
risk for paraaortic lymph node metastasis, whereas others 
high risk. Paraaortic lymphadenectomy was performed in 
high-risk patients and those with suspicious lymph nodes 
during the operation.
There was a patient who was suspected to have omental 
metastasis during the operation, so she underwent omen-
tal resection. Although no metastasis was detected in fro-
zen sections of the omentum, microscopic metastasis was 
found in the final histopathological evaluation. Since the 
distant metastasis of the patient with stage 4B could not 
be detected during the operation or preoperative PET/CT, 
lymphadenectomy was performed. 
Histopathologic Evaluation of Lymph Nodes
Uterus, bilateral adnexal tissues, lymph nodes and any 
other resected tissues were analysed by experienced pa-
thologists. 
Lymph nodes were fixed with 10% formalin and then 
embedded in paraffin. Paraffin blocks were sliced and pro-
cessed. Tissue sections were firstly stained with hematoxylin 
and eosin (H&E). If metastasis was detected in this proce-
dure, no further histological examination was performed. If 
the serial H&E sections were negative, immunohistochemi-
cal (IHC) methods were performed. PAN-cytokeratin was 
used for IHC evaluation. Histopathologically, the lymph 
nodes were defined as benign and malignant.
F-18 FDG PET/CT
PHILIPS GEMINI TF 16 Slice PET/CT scan was used for im-
aging. Patients with a blood glucose level below 200 mg/dL 
following an at least 6 hours of fasting received an intra-
venous 8–11 mCi FDG injection. The urinary bladder was 
evacuated approximately 60 minutes after the injection, and 
the body area from the vertex of the skull to the upper femur 
was scanned. CT images were captured initially (140 kV, 
100 mAs, 5 mm slice) followed by PET scans. PET scanning 
was performed at 9–10 bed positions depending on the 
height of the patient, each bed position lasting 90 seconds. 
The blood pool activity was taken into consideration 
while evaluating the FDG uptake by the lymph nodes on 
PET/CT. Regardless of the lesion size, a lymph node show-
ing a FDG uptake equal to or below the blood pool activ-
ity was considered negative for malignancy, and a FDG 
uptake above this threshold was considered positive for 
malignancy.
Data and Statistical Analyses
The histopathological examination results were consid-
ered as the reference standard in the evaluation of lymph 
node metastasis. A histopathological examination of the 
lymph nodes identified the lymph nodes as benign or ma-
lignant. The result of PET/CT was considered a true nega-
tive (TN) if it showed negative findings, and the result was 
considered false positive (FP) if the PET/CT showed posi-
tive findings in a histopathologically benign lymph node. 
The result of PET/CT was considered a true positive (TP) 
if it showed positive findings, and the result was consid-
ered a false negative (FN) if it showed negative findings in 
a histopathologically malignant lymph node. The accuracy, 
sensitivity and specificity of PET/CT in determining lymph 
node metastasis was calculated using a standard formula 
on a patient and lymph node basis. 
Sensitivity = TP/(TP + FN), Specificity = TN/(TN + FP),
Accuracy = (TP + TN)/(TP + FP + TN + FN)
RESULTS
Patients and Histopathologic Findings
The study included 80 patients who had endometrial 
cancer with a mean age of 62 ± 5.4 years (range 37–80). 
All patients underwent a pelvic lymphadenectomy, while 
50 patients underwent an additional paraaortic lymphad-
enectomy. Lymph node metastasis was detected in five pa-
tients, whereas 75 patients had no lymph node metastasis.
567
Emine Budak, Ahmet Yanarateş, The value of PET/CT in determining lymph node metastasis of endometrial cancer
www. journals.viamedica.pl/ginekologia_polska
Of the patients with lymph node metastasis, one had 
endometroid and 4 had nonendometroid (mixed = 2, se-
rous = 1, undifferentiated = 1) histology. The tumor grade 
was 2 in 1 patient and 3 in 4 patients. According to FIGO 
2009 staging, 2 of the patients were in stage 3C1, 2 of them 
were in stage 3C2, 1 of them was in stage 4B. 
In patients without lymph node metastasis the histo-
logic types were endometrioid carcinoma (n = 47), adeno-
carcinoma with squamous differentiation (n = 10), squa-
mous carcinoma (n = 8), undifferentiated carcinoma (n = 6), 
serous carcinoma (n = 2), clear cell carcinoma (n = 1) and 
mucinous carcinoma (n = 1). 22 cases were grade 1, 32 cases 
were grade 2 and 21 cases were grade 3. Of the 75 patients, 
40 were stage 1A, 12 were stage 1B, 10 were stage 2, 5 were 
stage 3A and 8 were stage 3B.
When evaluated on an lymph node basis, of the total 
1,471 lymph nodes, 1,046 were found in the pelvic area and 
425 in the paraaortic area in a histopathological examination. 
Of these lymph nodes, 1,433 (pelvic lymph node = 1018, par-
aaortic lymph node = 415) were benign and 38 (pelvic lymph 
node = 28, paraaortic lymph node = 10) were malignant (Tab. 1). 
Lymph Node Findings on PET/CT
Lymph node metastasis was detected in five out of 
80 patients, whereas 75 patients had no lymph node me-
tastasis. When evaluated on a patient basis, PET/CT was 
negative in 72 (TN) and positive (FP) in three of the 75 pa-
tients with a benign lymph node. PET/CT was positive in four 
(TP) and negative (FN) in one out of the five patients with 
at least one malignant lymph node on a histopathological 
examination. The results are presented in Table 2. When 
evaluated on a patient basis, the accuracy, sensitivity and 
specificity of PET/CT in detecting lymph node metastasis 
was 95%, 80% and, 96% respectively. 
When evaluated on an lymph node basis, PET/CT was 
positive in 20 (FP) and negative in 1,413 (TN) out of the 
1,433 lymph nodes that qualified histopathologically as 
benign. PET/CT was positive in 30 (TP) and negative in eight 
(FN) of the 38 lymph nodes that qualified as malignant upon 
a histopathological examination. The results are presented 
in Table 3. When evaluated on an lymph node basis, the 
accuracy, sensitivity and specificity of PET/CT in detect-
ing lymph node metastasis was 97.4%, 78.9% and 98.6%, 
respectively. Sample lymph node findings of PET/CT that 
were evaluated based on histopathological results are pre-
sented in Figure 1.
When 38 metastatic lymph nodes are grouped accord-
ing to their short diameters; 3 of them were ≤ 4 mm, 27 were 
5–9 mm, and 8 were ≥ 10 mm. PET/CT could not detect any 
metastatic lymph nodes with a short diameter of ≤ 4 mm, 
while it was true positive in 22 of those with a short diameter 
of 5–9 mm and in all of those with ≥ 10 mm. Thus, PET/CT 
was able to detect 22 of 30 metastatic lymph nodes with 
a short diameter of less than 10 mm (73.3%). The detection 
sensitivity of PET/CT was 0% (0/3), 81.4% (22/27) and 100% 
in metastatic lymph nodes with a short diameter of ≤ 4 mm, 
5–9 mm and ≥ 10 mm, respectively. 
DISCUSSION
Detecting the presence of lymph node metastasis in 
endometrial cancer is important in treatment decisions, 
as well as in predicting prognosis. However, only 20–25% 
of high-risk patients show nodal metastasis and up to 80% 
of patients undergo a futile systematic lymphadenec-
tomy  [15]. Furthermore, it has been demonstrated that 
a routine systematic lymphadenectomy offers no survival 
benefit in early-stage endometrial cancer [8, 9]. Lymph node 
dissection is currently considered the optimum method 
in determining the status of lymph nodes in endometrial 
cancer [11], although there are ongoing efforts to identify 
a preoperative, predictive non-invasive method. Determin-
ing the status of lymph nodes preoperatively avoids futile 
lymph node dissection, thereby decreasing morbidity and 
reducing costs. CT and MR are commonly used methods in 
Table 1. Histopathologically evaluated lymph nodes
Benign Malign Total
Pelvic lymph node 1018 28 1046
Paraaortic lymph node 415 10 425
Total 1433 38 1471
Results are shown as number
Table 2. Correlation of PET/CT results with pathologic findings on 
the basis of patient
PET/CT positive PET/CT negative Total
Pathology positive 4 1 5
Pathology negative 3 72 75
Total 7 73 80
Results are shown as number
Table 3. Correlation of PET/CT results with pathologic findings on 
the basis of lymph node
PET/CT 
positive
PET/CT 
negative Total
Pelvic lymph 
node
pathology positive 22 6 28
pathology negative 11 1007 1018
Paraaortic 
lymph node
pathology positive 8 2 10
pathology negative 9 406 415
Total 50 1421 1471
Results are shown as number
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the preoperative evaluation of patients with endometrial 
cancer. However, these conventional methods are predi-
cated on the size of the lymph nodes in the evaluation and 
a short diameter of ≥ 10 mm is the most accepted criterion 
for the identification of suspected lymph nodes. On this 
point, it is inevitable that < 10 mm short diameter metastatic 
lymph nodes are underestimated by CT or MR. However, 
FDG PET/CT provides functional data while also identifying 
morphological changes, suggesting that it may be superior 
to anatomical visualization alone in the evaluation of the 
status of lymph nodes [14]. In the present study, there were 
30 metastatic lymph nodes with < 10 mm short diameter. 
PET/CT was able to detect 22 of them (73.3%) and so had 
a great value in the detection of subcentimeter metastatic 
lymph nodes which have been disregarded by CT and MR. 
CT and MR are asserted to have a sensitivity of 29–66% 
and a specificity of 73–99% in various studies [12, 16, 17]. 
A study involving 287 patients with endometrial cancer 
found that PET/CT was more sensitive than MR in detect-
ing lymph node metastasis in a patient-based evaluation 
(70% vs. 34%), although specificity rates were similar (95.4% 
vs. 95%). The sensitivity and specificity of PET/CT were found 
to be 79.4% and 96.7% in an lymph node-based evaluation, 
with MR showing rates of 51.6% and 97.6%, respectively 
[18]. In a meta-analysis of 13 patient-based studies involv-
ing a total of 861 patients with endometrial cancer, the 
Figure 1. (A–D): Axial PET, CT, and fusion images of the lymph nodes evaluated as true negative (A, arrow), false negative (B, arrow), true positive 
(C, arrow), and false positive (D, arrow) on PET/CT are presented.; A. No lymph nodes with increased FDG uptake were observed in the pelvic or 
paraaortic regions on the PET/CT of a 44-year-old patient. No metastasis was determined upon a histopathological examination of the patient’s 52 
lymph nodes (44 pelvic and 8 paraaortic). The PET/CT result was a true negative for all 52 lymph nodes; B. No increased FDG uptake was observed 
in the lymph nodes seen in the pelvic and paraaortic regions in the PET/CT of a 74-year-old patient. A total of 28 lymph nodes were dissected from 
the pelvic (n: 21) and paraaortic (n: 7) regions in the case, in which metastasis was suspected intraoperatively. Metastasis was determined in the five 
lymph nodes in the right external and internal iliac regions, while other lymph nodes were determined to be benign. The PET/CT was false negative 
in those five lymph nodes and true negative in the other 23 lymph nodes; C. An increased FDG uptake was noted in one lymph node in the paraaortic 
region and in three lymph nodes in the pelvic region in a PET/CT of a 49-year-old patient. Metastasis was determined positive in the four lymph nodes 
histopathologically, and hence PET/CT findings were evaluated to be true positive; D. An increased FDG uptake was noted in three lymph nodes in 
the paraaortic region and in three lymph nodes in the pelvic region on a PET/CT. No metastasis was determined to be positive histopathologically in 
the total number of 30 lymph nodes (22 pelvic, 8 paraaortic) in this case. The PET/CT findings were considered false positive in six lymph nodes and 
true negative in the remaining 24 lymph nodes
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pooled specificity of FDG PET/CT in detecting lymph node 
metastasis was 94% (93–96%) and the pooled sensitivity was 
72% (63–80%) [14]. In another meta analysis of seven studies 
(243 patients with endometrial cancer), the pooled specific-
ity and sensitivity of PET or PET/CT in detecting lymph node 
metastasis was 94.7% (90.4–97.4%) and 63% (48.7–75.7%), 
respectively [19]. In a study by Crivellaro et al. [15] involving 
76 high-risk patients (serous/clear cell carcinoma, grade 
2 with deep myometrial invasion, grade 3) with clinical 
stage 1 endometrial cancer, the accuracy, sensitivity and 
specificity of PET/CT in detecting lymph node metastasis 
were 94.7%, 78.6% and 98.4% in a patient-based evalua-
tion, and 95.8%, 67.6% and 98.2% in an lymph node-based 
evaluation, respectively. In a study involving 40 patients 
with stage 1A–C endometrial cancer, the accuracy, sensi-
tivity and specificity of PET/CT in detecting lymph node 
metastasis were found to be 97.8%, 53.3% and 99.6% in 
a lymph node-based evaluation, respectively. When the 
lymph nodes were grouped according to their diameters, 
sensitivity was 16.7%, 66.7% and 93.3% in lesions measur-
ing ≤ 4 mm, 5–9 mm and ≥ 10 mm in diameter, respectively 
[20]. In a study by Kitajima et al. [21] involving patients with 
endometrial cancer and cervical cancer and using a similar 
lymph node classification, sensitivity was 12.5%, 66.7% and 
100%, respectively. Another study using FDG-PET detected 
no lymph node metastasis smaller than 6 mm [22]. The 
accuracy, sensitivity and specificity of PET/CT in detecting 
lymph node metastasis in the present study were found to 
be 95%, 80% and 96% in a patient-based evaluation, and 
97.4%, 78.9% and 98.6% in an lymph node-based evalua-
tion. Also, the detection sensitivity of PET/CT was 0%, 81.4% 
and 100% in metastatic lymph nodes with a short diameter 
of ≤ 4 mm, 5–9 mm and ≥ 10 mm, respectively. PET/CT could 
not detect any three metastatic nodes 4 mm or smaller. This 
is probably because of the currently used PET/CT techniques 
cannot detect micrometastatic diseases due to their low 
spatial resolution. The specificity of PET/CT in the present 
study was similar to literatüre results and, the sensitivity 
was higher than some of those reported in literature. The 
authors consider that lymph nodes evaluated in studies with 
variable sizes and the inability to recognize small-size lymph 
node metastasiss may result in different sensitivity rates 
being reported in such studies. For example, in our study, 
the rate of metastatic lymph nodes with a short diameter 
of ≤ 4 mm was 3/38 whereas in the study by Kitajima it 
was 16/45. Furthermore, the selection of low- or high-risk 
patients in some studies may have also affected the results. 
CONCLUCIONS
The present study is limited by its retrospective design 
and the relatively small number of patients with lymph 
node metastasis. That said, PET/CT showed high sensitivity, 
specificity and accuracy in the detection of lymph node 
metastasis, and had a great value in the detection of sub-
centimeter ones. Therefore, PET/CT can direct the surgical 
procedure even though it does not completely replace the 
surgical staging.
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